• Redx and Jounce Announce Recommended Business Combination

    Read more
  • Redx Provides Progress Update on RXC007 Clinical Programme

    Read more
  • Redx to Present at the 2nd Annual Wnt & β-Catenin Pathway Targeted Drug Development Summit

    Read more
  • Final Audited Results for the Year Ended 30 September 2022

    Read more
  • Redx Signs Clinical Trial Collaboration and Supply Agreement with MSD to evaluate RXC004 in combination with KEYTRUDA® (pembrolizumab) in PORCUPINE2 Study in Biliary Cancer

    Read more
  • Notice of Preliminary Results

    Read more
  • Redx Announces First Patient Dosed in Phase 2a Trial for RXC007

    Read more
  • Redx Presents Preclinical Data Confirming Anti-Fibrotic Effects of RXC007 in Immune Mediated Models, and Final Phase 1 Safety Data

    Read more
  • Redx to Present Poster on Encouraging Preclinical Fibrosis Data for RXC007 at the 21st International Colloquium on Lung and Airway Fibrosis

    Read more
  • Redx to Present Preclinical Data Poster for RXC007 at the European Respiratory Society International Congress

    Read more